为肥胖心脏病患者定制的康复项目(OPTICARE XL)的成本效果:随机对照试验结果
该研究基于荷兰三中心随机对照试验,评估为肥胖心脏病患者定制的OPTICARE XL康复项目与标准心脏康复的成本效果。18个月时两组QALYs相当(0.958 vs 0.965,P=.96),OPTICARE XL总体节省费用(-€4542),但直接与间接费用差异均不显著,结论为两组健康效果与成本无差异。
要点
- 肥胖心脏病患者定制康复与标准康复的QALYs相当(0.958 vs 0.965,P=.96)。
- OPTICARE XL总体节省€4542,但直接与间接费用差异不显著。
- 该经济评价未显示定制康复在健康效果或成本上优于标准康复。
核心结论
- OPTICARE XL定制康复与标准心脏康复在肥胖心脏病患者中健康效果与成本均无差异。
研究设计与样本
- 基于随机对照试验观察的成本效果分析,纳入201例BMI≥30 kg/m2转诊心脏康复的心脏病患者。
- 参与者随机分为OPTICARE XL组(N=102)或标准心脏康复组,在荷兰三个区域康复中心开展。
- OPTICARE XL含12周有氧与力量运动及饮食和身体活动行为教练,随后9个月含强化教育课程的后续护理。
- 标准心脏康复为6至12周有氧运动项目并辅以心血管生活方式教育。
- 经济评价时间 horizon 为18个月,从社会视角计算QALYs与成本,成本以2020年欧元报告,成本年贴现率4%,健康效应年贴现率1.5%。
主要发现
- OPTICARE XL组与标准康复组每患者健康获益相当(0.958 vs 0.965 QALYs,P=.96)。
- OPTICARE XL组总体节省成本(-€4542)。
- OPTICARE XL组直接成本高于标准康复组(€10,712 vs €9951),间接成本低于标准康复组(€51,789 vs €57,092),但差异均不显著。
临床怎么用
- 对肥胖心脏病患者,定制康复项目未显示额外健康获益或成本优势,标准心脏康复仍可作为常规选择。
局限性
- 直接与间接成本差异均不显著,总体成本节省的稳健性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost-effectiveness of a cardiac rehabilitation (CR) program specifically designed for cardiac patients with obesity vs standard CR. DESIGN: Cost-effectiveness analysis based on observations in a randomized controlled trial. SETTING: Three regional CR centers in the Netherlands. PARTICIPANTS: Cardiac patients (N=201) with obesity (BMI≥30 kg/m2) referred to CR. INTERVENTIONS: Participants were randomized to a CR program specifically designed for patients with obesity (OPTICARE XL; N=102) or standard CR. OPTICARE XL included aerobic and strength exercise and behavioral coaching on diet and physical activity during 12 weeks, followed by a 9-month after-care program with "booster" educational sessions. Standard CR consisted of a 6- to 12-week aerobic exercise program, supplemented with cardiovascular lifestyle education. MAIN OUTCOME MEASURES: An economic evaluation, with an 18-month time horizon, in terms of quality-adjusted life years (QALYs) and costs from the societal perspective was performed. Costs were reported in 2020 Euros, discounted at a 4% annual rate, and health effects were discounted at a 1.5% annual rate. RESULTS: OPTICARE XL CR and standard CR resulted in comparable health gain per patient (0.958 vs 0.965 QALYs, respectively; P=.96). Overall, OPTICARE XL CR saved costs (-€4542) compared with the standard CR group. The direct costs for OPTICARE XL CR were higher than for standard CR (€10,712 vs €9951), whereas indirect costs were lower (€51,789 vs €57,092), but these differences were not significant. CONCLUSIONS: This economic evaluation showed no differences between OPTICARE XL CR and standard CR in health effects and costs in cardiac patients with obesity.
引用
- Visser LA, den Uijl I, Redekop WK, et al. Cost-Effectiveness of a Cardiac Rehabilitation Program Specifically Designed for Patients With Obesity Within the OPTICARE XL Randomized Controlled Trial. Arch Phys Med Rehabil. 2023. PMID: 36868490. doi:10.1016/j.apmr.2023.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。